We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
The most recent trading session ended with Merck (MRK - Free Report) standing at $97.45, reflecting a -0.5% shift from the previouse trading day's closing. The stock's performance was behind the S&P 500's daily gain of 0.92%. Elsewhere, the Dow gained 0.31%, while the tech-heavy Nasdaq added 2.03%.
Heading into today, shares of the pharmaceutical company had lost 0.44% over the past month, lagging the Medical sector's gain of 3.83% and the S&P 500's gain of 0.81% in that time.
The upcoming earnings release of Merck will be of great interest to investors. The company's earnings report is expected on February 4, 2025. The company's upcoming EPS is projected at $1.69, signifying a 5533.33% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $15.57 billion, up 6.43% from the year-ago period.
Investors should also pay attention to any latest changes in analyst estimates for Merck. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 3.25% fall in the Zacks Consensus EPS estimate. Merck is holding a Zacks Rank of #3 (Hold) right now.
From a valuation perspective, Merck is currently exchanging hands at a Forward P/E ratio of 10.58. This expresses a discount compared to the average Forward P/E of 13.04 of its industry.
We can additionally observe that MRK currently boasts a PEG ratio of 1.18. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. MRK's industry had an average PEG ratio of 1.37 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 195, positioning it in the bottom 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
The most recent trading session ended with Merck (MRK - Free Report) standing at $97.45, reflecting a -0.5% shift from the previouse trading day's closing. The stock's performance was behind the S&P 500's daily gain of 0.92%. Elsewhere, the Dow gained 0.31%, while the tech-heavy Nasdaq added 2.03%.
Heading into today, shares of the pharmaceutical company had lost 0.44% over the past month, lagging the Medical sector's gain of 3.83% and the S&P 500's gain of 0.81% in that time.
The upcoming earnings release of Merck will be of great interest to investors. The company's earnings report is expected on February 4, 2025. The company's upcoming EPS is projected at $1.69, signifying a 5533.33% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $15.57 billion, up 6.43% from the year-ago period.
Investors should also pay attention to any latest changes in analyst estimates for Merck. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 3.25% fall in the Zacks Consensus EPS estimate. Merck is holding a Zacks Rank of #3 (Hold) right now.
From a valuation perspective, Merck is currently exchanging hands at a Forward P/E ratio of 10.58. This expresses a discount compared to the average Forward P/E of 13.04 of its industry.
We can additionally observe that MRK currently boasts a PEG ratio of 1.18. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. MRK's industry had an average PEG ratio of 1.37 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 195, positioning it in the bottom 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.